A comparative analysis of phyto-components on EGFR binding, viability, and migration in HPV positive ME180 and HPV negative C33A cervical cancer cells
- PMID: 37964051
- DOI: 10.1007/s12032-023-02223-2
A comparative analysis of phyto-components on EGFR binding, viability, and migration in HPV positive ME180 and HPV negative C33A cervical cancer cells
Abstract
A need for effective implementation of cervical cancer (CC) even in developed countries insist the urge for developing an effective drug molecule to treat CC. Previously, we showed an inverse correlation between survival of CC patients and epidermal growth factor (EGF) receptor (EGFR) levels. Newer tyrosine kinase inhibitors to treat CC are being constantly pursued. In this context, the proposed study is an attempt to perform a comparative analysis using 20 phyto-components to determine the effective lead molecule. Molecular docking was utilized to determine the comparative efficacy of 20 phyto-components in binding to EGFR. It was then validated by cell viability, mitochondrial membrane potential, apoptosis, migration, and matrix metalloproteinase (MMP-2) in human papilloma virus (HPV) positive and HPV negative CC cells using top nine phyto-components based on computational screening. Computational analysis identified nine phyto-components out of which five compounds were effective in reducing the survival, mitochondrial membrane potential, apoptosis, migration, and MMP-2 secretion. EGCG, plumbagin, quercetin, emodin, and naringenin were identified as effective molecules in attenuating CC survival, proliferation, and migration.
Keywords: C33A; EGFR; HPV; ME180; Migration; Phyto-components.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Plumbagin as a preferential lead molecule to combat EGFR-driven matrix abundance and migration of cervical carcinoma cells.Med Oncol. 2024 Mar 23;41(4):89. doi: 10.1007/s12032-024-02332-6. Med Oncol. 2024. PMID: 38520625
-
EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells.Med Oncol. 2023 Aug 7;40(9):261. doi: 10.1007/s12032-023-02135-1. Med Oncol. 2023. PMID: 37544940
-
A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer.Int J Biol Macromol. 2022 Jan 1;194:179-187. doi: 10.1016/j.ijbiomac.2021.11.117. Epub 2021 Nov 27. Int J Biol Macromol. 2022. PMID: 34848237 Review.
-
E6/E7 oncoproteins of high risk HPV-16 upregulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells.Int J Clin Exp Pathol. 2015 May 1;8(5):4981-9. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191191 Free PMC article.
-
Exploring the utility of FTS as a bonafide binding partner for EGFR: A potential drug target for cervical cancer.Comput Biol Med. 2023 Dec;167:107592. doi: 10.1016/j.compbiomed.2023.107592. Epub 2023 Nov 4. Comput Biol Med. 2023. PMID: 37976824 Review.
Cited by
-
Potential JAK2 Inhibitors from Selected Natural Compounds: A Promising Approach for Complementary Therapy in Cancer Patients.Evid Based Complement Alternat Med. 2024 Apr 26;2024:1114928. doi: 10.1155/2024/1114928. eCollection 2024. Evid Based Complement Alternat Med. 2024. PMID: 38706884 Free PMC article.
-
Epinephrine augments the phosphorylation of EGFR and promote the DNA synthesis and migration of cervical cancer cells.3 Biotech. 2025 May;15(5):125. doi: 10.1007/s13205-025-04285-7. Epub 2025 Apr 14. 3 Biotech. 2025. PMID: 40242059
-
A Combination of Flavonoids Suppresses Cell Proliferation and the E6 Oncogenic Pathway in Human Papillomavirus-Transformed Cells.Pathogens. 2025 Feb 24;14(3):221. doi: 10.3390/pathogens14030221. Pathogens. 2025. PMID: 40137706 Free PMC article.
-
Plumbagin as a preferential lead molecule to combat EGFR-driven matrix abundance and migration of cervical carcinoma cells.Med Oncol. 2024 Mar 23;41(4):89. doi: 10.1007/s12032-024-02332-6. Med Oncol. 2024. PMID: 38520625
References
-
- Muthusami S, Sabanayagam R, Periyasamy L, Muruganantham B, Park WY. A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer. Int J Biol Macromol. 2022;194:179–87. https://doi.org/10.1016/j.ijbiomac.2021.11.117 . - DOI - PubMed
-
- Mohan A, Krishnamoorthy S, Sabanayagam R, Schwenk G, Feng E, Ji HF, Sridhar M. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer. Eur J Pharmacol. 2023. https://doi.org/10.1016/j.ejphar.2023.175961 . - DOI - PubMed
-
- Muthusami S, Prabakaran DS, An Z, Yu JR, Park WY. EGCG suppresses fused toes homolog protein through p53 in cervical cancer cells. Mol Biol Rep. 2013;40(10):5587–96. https://doi.org/10.1007/s11033-013-2660-x . - DOI - PubMed
-
- Aarthy M, Panwar U, Singh SK. Structural dynamic studies on identification of EGCG analogues for the inhibition of human papillomavirus E7. Sci Rep. 2020;10(1):8661. https://doi.org/10.1038/s41598-020-65446-7 . - DOI - PubMed - PMC
-
- Khan MA, Hussain A, Sundaram MK, Alalami U, Gunasekera D, Ramesh L, Hamza A, Quraishi U. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol Rep. 2015;33(4):1976–84. https://doi.org/10.3892/or.2015.3802 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous